AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02990338
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous
Trial: NCT02990338
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: capsule Route of administration: oral
Trial: NCT02990338
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
Trial: NCT03430869
Drug: F-18-THK-5351
RxNorm normalized name: THK-5351 F-18
DrugBank: THK-5351 (DB19222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
Trial: NCT00748072
Drug: DDAVP
RxNorm normalized name: DDAVP
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.3 mcg/kg subcutaneous
Trial: NCT00748072
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline solution 1 ml subcutaneous
Trial: NCT03622801
Drug: Iopromide (Ultravist, BAY86-4877)
RxNorm normalized name: Iopromide
DrugBank: Iopromide (DB09156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
Trial: NCT02631772
Drug: Sofosbuvir/Ledipasvir x 12 weeks
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02631772
Drug: Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00725517
Drug: Icodextrin
RxNorm normalized name: Icodextrin
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
Trial: NCT03762369
Drug: CKD-351
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day
Trial: NCT03762369
Drug: Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: once a day
Trial: NCT03762369
Drug: D930
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: three times a day
Trial: NCT02943564
Drug: Rapastinel
RxNorm normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapastinel pre-filled syringes for weekly IV injections.
Trial: NCT04700839
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
Trial: NCT04700839
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
Trial: NCT03891264
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
Trial: NCT01778439
Drug: OMP-52M51
RxNorm normalized name: OMP-52M51
DrugBank: Brontictuzumab (DB12737)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02095782
Drug: Intercalated combination of chemotherapy and erlotinib
RxNorm normalized name: combinations of levothyroxine and liothyronine
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primary therapy stage:~Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.~Maintenance therapy stage:~Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death.
Trial: NCT01556425
Drug: Vivitrol
RxNorm normalized name: Vivitrol
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
Trial: NCT01381848
Drug: Doripenem
RxNorm normalized name: Doripenem
DrugBank: Doripenem (DB06211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients \<8 weeks CA.
Trial: NCT01381848
Drug: Doripenem
RxNorm normalized name: Doripenem
DrugBank: Doripenem (DB06211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients \>=8 weeks CA.
Trial: NCT03126695
Drug: Ticagrelor granule
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A P2Y12 receptor inhibitor provided as granule for suspension.
Trial: NCT03126695
Drug: Ticagrelor pediatric tablets
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.
Trial: NCT03126695
Drug: Ticagrelor pediatric tablets suspended in water
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
Trial: NCT03126695
Drug: Ticagrelor immediate release (IR) tablets (Commercial tablet)
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
Trial: NCT02467738
Drug: Cesium-131
RxNorm normalized name: Cesium-131
DrugBank: Cesium Cs-131 (DB19250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo brachytherapy with Cesium-131
Trial: NCT00787462
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
Trial: NCT02005419
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Trial: NCT02005419
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Trial: NCT00844415
Drug: dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.14 mg/kg BID to a max 150 mg BID
Trial: NCT01922687
Drug: amlodipine plus atorvastatin (Caduet)
RxNorm normalized name: amlodipine / atorvastatin
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01922687
Drug: amlodipine (Norvasc)
RxNorm normalized name: amlodipine Oral Tablet [Norvasc]
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00993265
Drug: N-Acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
Trial: NCT00642395
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bortezomib-Melphalan
Trial: NCT00047099
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00047099
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00047099
Drug: goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00047099
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03141671
Drug: GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Trial: NCT03141671
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Trial: NCT03141671
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Trial: NCT03141671
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
Trial: NCT03141671
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Trial: NCT03560973
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ramucirumab/ placebo was added to gemcitabine
Trial: NCT03560973
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ramucirumab/ placebo was added to gemcitabine
Trial: NCT02053857
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02782468
Drug: Pevonedistat 25 mg/m^2
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat 25 mg/m\^2 intravenous infusion.
Trial: NCT06395194
Drug: Cardiac outcomes on treatment with valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Valsartan treatment started at a dosage of 80 mg daily. If BP did not reach \<140/90 mmHg, the valsartan dose was doubled to 160 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps.
Trial: NCT06395194
Drug: Cardiac outcomes on treatment with amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase (rolled over). Amlodipine treatment started at 5 mg daily. If BP did not reach \<140/90 mmHg, the amlodipine dose was doubled to 10 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps.
Trial: NCT02171793
Drug: BI 1744 CL
RxNorm normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02782468
Drug: Pevonedistat 44 mg/m^2
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat 44 mg/m\^2 intravenous infusion.
Trial: NCT02782468
Drug: Pevonedistat 10 mg/m^2
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat 10 mg/m\^2 intravenous infusion.
Trial: NCT02782468
Drug: Pevonedistat 20 mg/m^2
DrugBank: Pevonedistat (DB11759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat 20 mg/m\^2 intravenous infusion.
Trial: NCT02782468
Drug: Azacitidine 75 mg/m^2
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.
Trial: NCT04563494
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prevention of post op nausea and vomiting
Trial: NCT02587650
Drug: Capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02587650
Drug: Ceritinib
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02587650
Drug: Entrectinib
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02587650
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02581202
Drug: lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet
Trial: NCT02581202
Drug: lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet
Trial: NCT00313170
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: intramuscular injection 250 mg \& 500 mg
Trial: NCT00358488
Drug: GSK159797 (10, 15, and 20mcg)
RxNorm normalized name: GSK159797
DrugBank: GSK159797 (DB05043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK159797 (10, 15, and 20mcg)
Trial: NCT00358488
Drug: salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol
Trial: NCT01200810
Drug: bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00208819
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00208819
Drug: quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00208819
Drug: olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00358488
Drug: salmeterol 50mcg
RxNorm normalized name: FLUTICAS 500/SALMETEROL 50MCG INHL DISK
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: salmeterol 50mcg
Trial: NCT01834014
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT00208819
Drug: divalproex
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03133637
Drug: ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible infants will receive ceftriaxone as standard of care for sepsis
Trial: NCT01246583
Drug: Vehicle 1
RxNorm normalized name: meningococcal group B vaccine 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen 0.1 MG/ML / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle 0.05 MG/ML [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle 1 twice daily for 4 weeks
Trial: NCT01246583
Drug: Vehicle 2
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle 2 twice daily for 4 weeks
Trial: NCT00151099
Drug: high caloric drink with protein
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00449501
Drug: Budesonide/formoterol pMDI
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00449501
Drug: Budesonide HFA pMDI
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05054114
Drug: Interferon gamma human recombinant (IFN-G)
RxNorm normalized name: interferon gamma, porcine recombinant
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nasal form
Trial: NCT00621478
Drug: lorazepam or diazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push.
Trial: NCT00322283
Drug: Oglemilast
RxNorm normalized name: Oglemilast
DrugBank: Oglemilast (DB12375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oglemilast, 15mg once per day, oral administration
Trial: NCT03673670
Drug: Tiotropium/olodaterol (Respimat)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An anticholinergic/β-agonist combination medication
Trial: NCT01038817
Drug: Duraphat
RxNorm normalized name: testosterone enanthate Injectable Solution [Durathate]
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
Trial: NCT00298350
Drug: GS-9137 - A Novel HIV-1 Integrase Inhibitor
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02159950
Drug: Tasquinimod
RxNorm normalized name: Tasquinimod
DrugBank: Tasquinimod (DB05861)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01638520
Drug: Pascolizumab
RxNorm normalized name: Pascolizumab
DrugBank: Pascolizumab (DB06560)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
Trial: NCT02116777
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02116777
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02569814
Drug: Fimasartan/Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02284126
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied powder and paste to surgical site at time of closure.